Basal autophagy is pivotal for Hodgkin and Reed-Sternberg cells' survival and growth revealing a new strategy for Hodgkin lymphoma treatment

As current classical Hodgkin lymphoma (cHL) treatment strategies have pronounced side-effects, specific inhibition of signaling pathways may offer novel strategies in cHL therapy. Basal autophagy, a regulated catabolic p
As current classical Hodgkin lymphoma (cHL) treatment strategies have pronounced side-effects, specific inhibition of signaling pathways may offer novel strategies in cHL therapy. Basal autophagy, a regulated catabolic pathway to degrade cell's own components, is in cancer linked with both, tumor suppression or promotion. The finding that basal autophagy enhances tumor cell survival would thus lead to immediately testable strategies for novel therapies. Thus, we studied its contribution in cHL.We found constitutive activation of autophagy in cHL cell lines and primary tissue. The expression of key autophagy-relevant proteins (e.g. Beclin-1, ULK1) and LC3 processing was increased in cHL cells, even in lymphoma cases. Consistently, cHL cells exhibited elevated numbers of autophagic vacuoles and intact autophagic flux. Autophagy inhibition with chloroquine or inactivation of ATG5 induced apoptosis and reduced proliferation of cHL cells. Chloroquine-mediated inhibition of basal autophagy significantly impaired HL growth in-vivo in NOD SCID γc-/- (NSG) mice. We found that basal autophagy plays a pivotal role in sustaining mitochondrial function.We conclude that cHL cells require basal autophagy for growth, survival and sustained metabolism making them sensitive to autophagy inhibition. This suggests basal autophagy as useful target for new strategies in cHL treatment.
show moreshow less

Download full text files

Export metadata

  • Export Bibtex
  • Export RIS
Metadaten
Author:Katrin Birkenmeier, Katharina Moll, Sebastian Newrzela, Sylvia Hartmann, Stefan Dröse, Martin-Leo Hansmann
URN:urn:nbn:de:hebis:30:3-412924
DOI:http://dx.doi.org/10.18632/oncotarget.10300
ISSN:1949-2553
Pubmed Id:http://www.ncbi.nlm.nih.gov/pubmed?term=27366944
Parent Title (English):OncoTarget
Publisher:Impact Journals LLC
Place of publication:[S. l.]
Document Type:Article
Language:English
Date of Publication (online):2016/06/27
Date of first Publication:2016/06/27
Publishing Institution:Universitätsbibliothek Johann Christian Senckenberg
Release Date:2016/07/11
Tag:B-cell lymphoma; Hodgkin lymphoma; autophagy; lymphoma pathogenesis; targeted therapy
Volume:2016
Pagenumber:10
First Page:1
Last Page:10
Note:
Copyright @ 2016 Impact Journals, LLC. Impact Journals is a registered trademark of Impact Journals, LLC
HeBIS PPN:39989392X
Institutes:Medizin
Dewey Decimal Classification:610 Medizin und Gesundheit
Sammlungen:Universitätspublikationen
Licence (German):License LogoCreative Commons - Namensnennung 3.0

$Rev: 11761 $